Navigation Links
RZN Nutraceuticals Receives United States Patent & Trademark Office Notice of Allowance for Proprietary HerbaZorb(TM) Absorption and Delivery System Technology Used in Popular Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) Products
Date:9/11/2009

MIAMI, Sept. 11 /PRNewswire/ -- RZN Nutraceuticals, Inc.,(www.rznnutra.com) a leading developer of proven effective herbal products which have been clinically tested on sufferers of severe arthritis and migraines has announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for the firm's absorption and delivery system process methodology patent application, a technology RZN has named HerbaZorb(TM). Two of the firm's most popular product offerings, Arthri-Zen Relief(R) and Migra-Zen Relief(R) PLUS capsules already use the technology in their manufacture. The use of this preparation method ensures the rapid and effective absorption of active ingredients.

"We're very pleased that the U.S. Patent and Trademark Office has recognized HerbaZorb as a patentable delivery system that allows herbal supplements and functional foods to be absorbed with full potency intact," said Mark Lubin, founder of RZN Nutraceuticals, Inc., and a 25-year veteran biomedical engineer and research scientist in the fields of orthopedics, joint diseases, implantable cardiac devices, materials science and medical chemistry.

Among the proprietary characteristics of HerbaZorb noted in the patent application are that it protects beneficial phytochemicals of herbs and herbal extracts from being digested prior to entering the bloodstream, providing a significant advantage to both producers of herbal products and those who consume them. "The basis for our patent is that our delivery system represents a breakthrough in the field of bioavailability, the process by which active ingredients are delivered to the bloodstream intact, ensuring their maximum usefulness in the body." Mr. Lubin commented.

According to company President Robert Hunt, "It is very satisfying to gain this important recognition for HerbaZorb, especially as we continue making the process available to other manufacturers who want us to prepare their herbal ingredients using this new technology."

Clinical researchers have long studied the role absorption plays in the bioavailability of active ingredients ingested into the body. According to the Physician's Desk Reference, only 10 to 20 percent of vitamins and minerals taken orally in tablet form are actually absorbed into the bloodstream.

"My goal has always been to develop the most effective and natural pain relief formulations possible, which resulted in the Arthri-Zen Relief(R) and Migra-Zen Relief(R) PLUS family of products," Mr. Lubin stated. "With the advances in absorption offered by HerbaZorb, we can ensure that everyone in the industry using herbal blends can benefit from maximum bioavailability so the active ingredients in them are utilized most fully by the human body."

RZN Nutraceuticals' products are marketed direct to natural accounts, through private label, catalogue sales, practitioner offices, health clubs and on company's website, www.rznnutra.com. Future distribution plans include national drug store chains and natural supplement outlets.

For more information on Migra-Zen Relief Plus(R) or the three Arthri-Zen Relief(R) formulations, visit www.rznnutra.com, or contact RZN President Robert Hunt 904-213-8232.

For media inquiries, contact Jennifer Bryan of Christie Communications (www.christiecomm.com) at 805-969-3744.


'/>"/>
SOURCE RZN Nutraceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals
2. Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line
3. Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
4. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
5. Nutraceuticals could prevent diabetes
6. Berkeley Premium Nutraceuticals Pushes Forward
7. UM receives grant to support graduate students in the family nurse practitioner program
8. Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R)
9. CBM-US Receives $3 Million Grant To Fund HIV/AIDS Prevention and Care Efforts in Africa
10. Solos Endoscopy, Inc. Receives Purchase Order from One of the Major Healthcare Systems in Missouri
11. Ascenta Therapeutics Receives Clearance to Initiate Clinical Trials With AT-406
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: